Theralase Technologies Inc. (TSXV:TLT)

Market Cap	39.84M
Revenue (ttm)	1.00M
Net Income (ttm)	-4.35M
Shares Out	257.06M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,381
Average Volume	229,920
Open	0.1650
Previous Close	0.1550
Day's Range	0.1500 - 0.1650
52-Week Range	0.1500 - 0.3350
Beta	0.55
RSI	34.68
Earnings Date	Nov 28, 2025

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2024, Theralase Technologies's revenue was 1.03 million, a decrease of -3.45% compared to the previous year's 1.07 million. Losses were -4.26 million, -6.89% less than in 2023.